Thomas Grimmsmann

853 total citations
23 papers, 603 citations indexed

About

Thomas Grimmsmann is a scholar working on Surgery, Geriatrics and Gerontology and Molecular Biology. According to data from OpenAlex, Thomas Grimmsmann has authored 23 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 6 papers in Geriatrics and Gerontology and 5 papers in Molecular Biology. Recurrent topics in Thomas Grimmsmann's work include Pharmaceutical Practices and Patient Outcomes (6 papers), Pancreatic function and diabetes (5 papers) and Medication Adherence and Compliance (4 papers). Thomas Grimmsmann is often cited by papers focused on Pharmaceutical Practices and Patient Outcomes (6 papers), Pancreatic function and diabetes (5 papers) and Medication Adherence and Compliance (4 papers). Thomas Grimmsmann collaborates with scholars based in Germany and Denmark. Thomas Grimmsmann's co-authors include Wolfgang Himmel, Ingo Rustenbeck, Jean‐François Chenot, Henning Beck‐Nielsen, Klaus Levin, Michael M. Kochen, Marco Meyer, H. H. Klein, Harald Klein and Kirsten Unthan‐Fechner and has published in prestigious journals such as Diabetes, Journal of Hepatology and Diabetologia.

In The Last Decade

Thomas Grimmsmann

23 papers receiving 593 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas Grimmsmann Germany 12 178 153 124 84 81 23 603
Bianca Kollhorst Germany 14 40 0.2× 84 0.5× 45 0.4× 68 0.8× 186 2.3× 51 721
Ujjaini Khanderia United States 12 73 0.4× 91 0.6× 42 0.3× 32 0.4× 56 0.7× 23 379
Willy Marcos Valencia United States 13 181 1.0× 135 0.9× 76 0.6× 223 2.7× 72 0.9× 35 908
Diane Chau United States 9 78 0.4× 143 0.9× 42 0.3× 103 1.2× 78 1.0× 17 583
William Wang United States 10 76 0.4× 61 0.4× 17 0.1× 68 0.8× 38 0.5× 19 460
In‐Sun Choi South Korea 11 86 0.5× 57 0.4× 16 0.1× 79 0.9× 79 1.0× 29 509
Douglas Barthold United States 15 56 0.3× 143 0.9× 58 0.5× 143 1.7× 94 1.2× 45 740
Todd Hobbs United States 17 105 0.6× 150 1.0× 26 0.2× 106 1.3× 90 1.1× 27 783
Ken Paterson United Kingdom 16 80 0.4× 112 0.7× 21 0.2× 69 0.8× 113 1.4× 47 777
D Schröder-Bernhardi Germany 9 34 0.2× 36 0.2× 36 0.3× 50 0.6× 85 1.0× 19 442

Countries citing papers authored by Thomas Grimmsmann

Since Specialization
Citations

This map shows the geographic impact of Thomas Grimmsmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Grimmsmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Grimmsmann more than expected).

Fields of papers citing papers by Thomas Grimmsmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Grimmsmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Grimmsmann. The network helps show where Thomas Grimmsmann may publish in the future.

Co-authorship network of co-authors of Thomas Grimmsmann

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Grimmsmann. A scholar is included among the top collaborators of Thomas Grimmsmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Grimmsmann. Thomas Grimmsmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grimmsmann, Thomas & Wolfgang Himmel. (2023). Privatverordnungen von Benzodiazepinen und Z-Substanzen in Ost- und Westdeutschland – eine Sekundärdatenanalyse. Das Gesundheitswesen. 85(12). 1213–1219. 2 indexed citations
2.
Grimmsmann, Thomas, Karel Kostev, & Wolfgang Himmel. (2022). The role of private prescriptions in benzodiazepine and Z-drug use—a secondary analysis of office-based prescription data. Deutsches Ärzteblatt international. 119(21). 380–381. 5 indexed citations
3.
4.
Grimmsmann, Thomas & Wolfgang Himmel. (2020). The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. European Journal of Clinical Pharmacology. 77(1). 107–115. 23 indexed citations
5.
Grimmsmann, Thomas, Markus Harden, Thomas Fiß, & Wolfgang Himmel. (2018). The influence of hospitalisation on the initiation, continuation and discontinuation of benzodiazepines and Z-drugs – an observational study. Swiss Medical Weekly. 148(506). w14590–w14590. 6 indexed citations
6.
7.
Grimmsmann, Thomas & Wolfgang Himmel. (2016). Comparison of therapy persistence for fixed versus free combination antihypertensives: a retrospective cohort study. BMJ Open. 6(11). e011650–e011650. 15 indexed citations
8.
Grimmsmann, Thomas & Wolfgang Himmel. (2013). Persistence of antihypertensive drug use in German primary care: a follow-up study based on pharmacy claims data. European Journal of Clinical Pharmacology. 70(3). 295–301. 11 indexed citations
9.
Grimmsmann, Thomas & Wolfgang Himmel. (2011). Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?. European Journal of Clinical Pharmacology. 67(8). 847–854. 52 indexed citations
10.
Chenot, Jean‐François, et al.. (2010). Appropriateness of treatment recommendations for PPI in hospital discharge letters. European Journal of Clinical Pharmacology. 66(12). 1265–1271. 73 indexed citations
11.
Grimmsmann, Thomas & Wolfgang Himmel. (2009). Polypharmacy in primary care practices: an analysis using a large health insurance database. Pharmacoepidemiology and Drug Safety. 18(12). 1206–1213. 45 indexed citations
12.
Grimmsmann, Thomas & Wolfgang Himmel. (2009). Inwieweit bilden definierte Tagesdosen (DDD) die tatsächlich verordneten Tagesdosen ab? Eine Analyse ambulanter Verordnungsdaten. Das Gesundheitswesen. 72(7). 412–418. 4 indexed citations
13.
Grimmsmann, Thomas, et al.. (2007). The influence of hospitalisation on drug prescription in primary care – a large-scale follow-up study. European Journal of Clinical Pharmacology. 63(8). 783–790. 67 indexed citations
14.
Meyer, Marco, Klaus Levin, Thomas Grimmsmann, Henning Beck‐Nielsen, & H. H. Klein. (2002). Insulin signalling in skeletal muscle of subjects with or without Type II-diabetes and first degree relatives of patients with the disease. Diabetologia. 45(6). 813–822. 49 indexed citations
15.
Grimmsmann, Thomas, et al.. (2002). Delays in insulin signaling towards glucose disposal in human skeletal muscle. Journal of Endocrinology. 172(3). 645–651. 8 indexed citations
16.
Klein, Harald, et al.. (2002). Differential modulation of insulin actions by dexamethasone: studies in primary cultures of adult rat hepatocytes. Journal of Hepatology. 37(4). 432–440. 25 indexed citations
17.
Meyer, Marco, Klaus Levin, Thomas Grimmsmann, et al.. (2002). Troglitazone Treatment Increases Protein Kinase B Phosphorylation in Skeletal Muscle of Normoglycemic Subjects at Risk for the Development of Type 2 Diabetes. Diabetes. 51(9). 2691–2697. 27 indexed citations
18.
Rustenbeck, Ingo, et al.. (1999). Mitochondria Present in Excised Patches From Pancreatic B-cells May Form Microcompartments With ATP-Dependent Potassium Channels. Bioscience Reports. 19(2). 89–98. 7 indexed citations
19.
Schaefer, Stephan, et al.. (1998). Properties of tumour suppressor p53 in murine hepatocyte lines transformed by hepatitis B virus X protein.. Journal of General Virology. 79(4). 767–777. 21 indexed citations
20.
Grimmsmann, Thomas & Ingo Rustenbeck. (1998). Direct effects of diazoxide on mitochondria in pancreatic B‐cells and on isolated liver mitochondria. British Journal of Pharmacology. 123(5). 781–788. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bianca Kollhorst Breakdown of academic impact, for papers by Ujjaini Khanderia Breakdown of academic impact, for papers by Willy Marcos Valencia Breakdown of academic impact, for papers by Diane Chau Breakdown of academic impact, for papers by William Wang Breakdown of academic impact, for papers by In‐Sun Choi Breakdown of academic impact, for papers by Douglas Barthold Breakdown of academic impact, for papers by Todd Hobbs Breakdown of academic impact, for papers by Ken Paterson Breakdown of academic impact, for papers by D Schröder-Bernhardi
Rankless by CCL
2026